Premium
Mechlorethamine, procarbazine and prednisone for the treatment of resistant lymphoma in dogs
Author(s) -
Northrup N. C.,
Gieger T. L.,
Kosarek C. E.,
Saba C. F.,
LeRoy B. E.,
Wall T. M.,
Hume K. R.,
Childress M. O.,
Keys D. A.
Publication year - 2009
Publication title -
veterinary and comparative oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.864
H-Index - 34
eISSN - 1476-5829
pISSN - 1476-5810
DOI - 10.1111/j.1476-5829.2008.00170.x
Subject(s) - procarbazine , prednisone , vincristine , medicine , lymphoma , canine lymphoma , gastroenterology , chemotherapy , cyclophosphamide
Forty‐one dogs with resistant lymphoma were treated with a modified MOPP (mechlorethamine, vincristine, procarbazine and prednisone) protocol (MPP [mechlorethamine, procarbazine and prednisone] administered on a 21‐day cycle, shortened from the 28‐day MOPP cycle). The overall response rate to MPP was 34% for a median of 56 days (95% confidence interval 30–238). Seventeen percent of dogs had a complete response for a median duration of 238 days, 17% had a partial response for a median of 56 days and 32% had stable disease for a median of 24 days. Histological grade or cell morphology on cytology was associated with response. Minimal toxicity was observed with the MPP protocol, suggesting that further dose intensification or addition of another chemotherapeutic agent would be possible.